gms | German Medical Science

60th Annual Meeting of the German Society of Neurosurgery (DGNC)
Joint Meeting with the Benelux countries and Bulgaria

German Society of Neurosurgery (DGNC)

24 - 27 May 2009, Münster

Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib

Meeting Abstract

  • M.-E. Halatsch - Neurochirurgische Klinik und Poliklinik, Universitätsklinikum Heidelberg
  • S. Löw - Neurochirurgische Klinik und Poliklinik, Universitätsklinikum Heidelberg
  • K. Mursch - Zentralklinik Bad Berka, Neurochirurgische Klinik, Bad Berka
  • B. Orakcioglu - Neurochirurgische Klinik und Poliklinik, Universitätsklinikum Heidelberg
  • V. Vougioukas - Albert-Ludwigs-Universität, Abteilung Allgemeine Neurochirurgie, Freiburg
  • A. Unterberg - Neurochirurgische Klinik und Poliklinik, Universitätsklinikum Heidelberg

Deutsche Gesellschaft für Neurochirurgie. 60. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit den Benelux-Ländern und Bulgarien. Münster, 24.-27.05.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. DocMI.05-01

DOI: 10.3205/09dgnc192, URN: urn:nbn:de:0183-09dgnc1920

Published: May 20, 2009

© 2009 Halatsch et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Erlotinib, an EGFR tyrosine kinase inhibitor, exerts widely variable antiproliferative effects on human GBM cell lines in vitro and in vivo. As those effects are independent of EGFR baseline expression levels, more complex genetic properties may form the molecular basis of the erlotinib-sensitive and erlotinib-resistant GBM phenotypes. The aim of the current study was to determine candidate genes mediating cellular response of human GBM towards erlotinib.

Methods: Complementary RNAs from cell lines selected to represent the sensitive, intermediately responsive and resistant phenotypes, respectively, were hybridized to CodeLink Human Whole Genome Bioarrays.

Results: Expression analysis of prospectively selected 814 genes involved in major proliferation and apoptosis signaling pathways identified 19 genes the expression of which significantly correlated with phenotype. Functional annotation analysis revealed two (DUSP4, STAT1) and ten (CACNG4, FGFR4, HSPA1B, HSPB1, NFATC1, NTRK1, RAC1, SMO, TCF7L1, TGFB3) genes conclusively associated with sensitivity and resistance to erlotinib, respectively. Moreover, five genes (BDNF, CARD6, FOSL1, HSPA9B, MYC) involved in antiapoptotic pathways were unexpectedly found to be associated with sensitivity.

Conclusions: By analyzing gene expressions in cell lines with sensitive, intermediately responsive and resistant phenotypes, this study proposes candidate genes for GBM response to erlotinib. The ten gene candidates for conferring GBM resistance to erlotinib potentially represent worthwhile therapeutic targets, interfering with which may enhance the efficacy of erlotinib against GBM. Five additional genes warrant further investigation regarding their roles as putative co-targets of erlotinib.